OTIC Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa


Warning: file_get_contents(https://api.iextrading.com/1.0/stock/OTIC/company): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 402

Warning: file_get_contents(https://api.iextrading.com/1.0/stock/OTIC/quote): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 406

News: OTIC Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa

Time: Friday, March 02, 2018 12:15

Intraday Maximum Change: $-0.475 - -8.52% Minutes After: 168


Warning: Division by zero in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 449

Latest Quote: Change Since: $-6.05 - -INF% Days Since: 758

Snapshot of company's key stats at the time of the event

Market Cap: 165,337,299 Shares Outstanding: 30,337,119 Float: 30,294,157

Day's Short Interest: 1,005,731 Short Ratio: 2.94%

Institutional Ownership: 32.9% Insider Ownership: 0%

OTIC -

Sector: - Industry:

Subsidiary Scilex receives US FDA approval for non-opioid ZTlido (lidocaine topical system)


Warning: file_get_contents(https://api.iextrading.com/1.0/stock/SRNE/company): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 402

Warning: file_get_contents(https://api.iextrading.com/1.0/stock/SRNE/quote): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 406

News: Subsidiary Scilex receives US FDA approval for non-opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain; ZTlido uses novel technology demonstrating 12-Hour wear for efficient lidocaine delivery, even during exercise

Time: Wednesday, February 28, 2018 14:45

Link: http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-subsidiary-scilex-receives-us-fda-approval

Intraday Maximum Change: $0.925 - 9.273% Minutes After: 61


Warning: Division by zero in /home/n00bis5/public_html/alphadiz/wp/wp-content/themes/twentyseventeen-child/template-parts/post/content.php on line 449

Latest Quote: Change Since: $-9.05 - -INF% Days Since: 760

Snapshot of company's key stats at the time of the event

Market Cap: 698,755,673 Shares Outstanding: 82,692,979 Float: 0

Day's Short Interest: 3,111,259 Short Ratio: 1.01%

Institutional Ownership: 33.4% Insider Ownership: 0%

SRNE -

Sector: - Industry: